A Phase 2 interventional study of AR-17043 and PG043 in glaucoma/ocular hypertension

Study Description

Evaluating the Safety and Effectiveness of New Eye Drops for Glaucoma and High Eye Pressure

Study Details

Registry ID:

NCT06441643

Conditions:

Open Angle Glaucoma, Ocular Hypertension

Phase:

Phase 2

Target Enrollment:

426 participants

Start Date:

September 4, 2024

Age Range:

18–999 years

Healthy Volunteers:

No

Study Locations (12 sites)

• Piedmont Eye Center
  Lynchburg, VirginiaUnited States, United States
• James D. Branch Ophthalmology
  Winston-Salem, North CarolinaUnited States, United States
• Rochester Ophthalmological Group
  Rochester, New YorkUnited States, United States
• Scott & Christie and Associates, PC
  Cranberry Township, PennsylvaniaUnited States, United States
• Coastal Research Associates
  Roswell, GeorgiaUnited States, United States
• University Eye Specialists
  Maryville, TennesseeUnited States, United States
• Total Eye Care PA
  Memphis, TennesseeUnited States, United States
• Eye Center of Northern Colorado, PC
  Fort Collins, ColoradoUnited States, United States
• Eye Research Foundation
  Newport Beach, CaliforniaUnited States, United States
• Orange County Ophthalmology Medical Group
  Garden Grove, CaliforniaUnited States, United States
• United Medical Research Institute
  Inglewood, CaliforniaUnited States, United States
• North Bay Eye Associates
  Petaluma, CaliforniaUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →